BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST

La evaluación radiológica de respuesta a la quimioterapia se puede hacer con el criterio RECIST, considerado actualmente el método más objetivo de seguimiento de lesiones. Con el objetivo de buscar una curva general de respuesta, entre los años 2006 y 2008 estudiamos 21 pacientes con tumores pulmona...

Full description

Bibliographic Details
Main Authors:	Mauricio Canals L, Monzerrat Fernández G, Adolfo Barros R, Mauricio Mahave C, Pamela Salman B, Manuel Yañez G
Format:	Article
Language:	Spanish
Published:	Permanyer
Series:	Revista Chilena de Radiología
Subjects:	recist response curve
Online Access:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-93082009000200003&lng=en&tlng=en

Similar Items

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST LOOKING FOR A GENERAL RESPONSE CURVE TO CHEMOTHERAPY BASED ON RADIOLOGICAL EVALUATION WITH RECIST CRITERIA
by: Mauricio Canals L, et al.
Published: (2009-01-01)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
by: Hongge Liang, et al.
Published: (2020-04-01)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
by: Ching-Chung Ko, et al.
Published: (2021-07-01)

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
by: Kai Xiong, et al.
Published: (2024-07-01)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
by: Antoine Iannessi, et al.
Published: (2021-03-01)

Reproducing RECIST lesion selection via machine learning: Insights into intra and inter-radiologist variation
by: Teresa M. Tareco Bucho, et al.
Published: (2024-06-01)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
by: Ying Xu, et al.
Published: (2022-05-01)

Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
by: Dong Ho Lee, et al.
Published: (2021-12-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 1
by: Ashita Rastogi, et al.
Published: (2019-07-01)

Multilingual RECIST classification of radiology reports using supervised learning
by: Luc Mottin, et al.
Published: (2023-06-01)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
by: Hubert Beaumont, et al.
Published: (2023-10-01)

A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1)
by: Kathleen Ruchalski, et al.
Published: (2024-11-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)

Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?
by: Antoine Iannessi, et al.
Published: (2023-03-01)

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
by: Valentina Magri, et al.
Published: (2024-02-01)

Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma
by: Marwa Mohammed Hasan Tawfik, et al.
Published: (2020-05-01)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
by: Federica Grosso, et al.
Published: (2021-10-01)

RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads
by: Antoine Iannessi, et al.
Published: (2024-08-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
by: Mayte Delgado-Ureña, et al.
Published: (2018-09-01)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
by: Peng Song, et al.
Published: (2019-04-01)

Evaluation of liver tumour response by imagingKey points
by: Jules Gregory, et al.
Published: (2020-06-01)

Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects
by: Zhilong Xu, et al.
Published: (2024-10-01)

RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE
by: A. V. Novik, et al.
Published: (2019-09-01)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
by: Pierpaolo Trimboli, et al.
Published: (2018-05-01)

Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics
by: Mehdi Felfli, et al.
Published: (2024-12-01)

A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer
by: Wenfang Tang, et al.
Published: (2020-09-01)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
by: Kevin Zwirtz, et al.
Published: (2022-06-01)

Are radiologists ready to evaluate true response to immunotherapy?
by: Inci Kizildag Yirgin, et al.
Published: (2021-02-01)

Tumor response assessment on imaging following immunotherapy
by: Antonia M. Berz, et al.
Published: (2022-10-01)

Erratum: Tumor response assessment on imaging following immunotherapy
by: Frontiers Production Office
Published: (2023-03-01)

Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
by: Mariangela Parodi, et al.
Published: (2015-10-01)

Diffusion-weighted MR imaging diagnostic merits in the post-therapeutic assessment of musculoskeletal soft tissue sarcoma
by: Amr Farouk Ibrahim Moustafa, et al.
Published: (2019-11-01)

A single‐institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors
by: Raja Shaikh, et al.
Published: (2023-06-01)

Immunotherapy Assessment: A New Paradigm for Radiologists
by: Vincenza Granata, et al.
Published: (2023-01-01)

CIENCIA E IMAGINOLOGIA: ANÁLISIS CUANTITATIVO DE LA INVESTIGACIÓN RADIOLÓGICA
by: Mauricio Canals L

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
by: Vivek Subbiah, et al.
Published: (2017-02-01)

Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation
by: Nabeel Mansour, et al.
Published: (2024-06-01)

Response Assessment of Treated Hepatocellular Carcinoma
by: Amitkumar J. Choudhari, et al.
Published: (2023-09-01)

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial
by: Masahiro Hatooka, et al.
Published: (2018-06-01)